Video

Additional Key Data Updates from ASH 2022 on Treatment of LBCL

Author(s):

Manali Kamdar, MDMatthew A. Lunning, DO, FACP

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Related Videos
Sattva S. Neelapu, MD
Julie M. Vose, MD, MBA
Lakshmi Nayak, MD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Jakub Svoboda, MD
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Related Content
Lakshmi Nayak, MD, director, Center for CNS Lymphoma, Dana-Farber Cancer Institute; associate professor, neurology, Harvard Medical School
June 11th 2024

Axi-Cel Shows Safety, Clinical Activity in R/R Primary and Secondary CNS Lymphomas

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Mark Frattini, MD, PhD
June 5th 2024

UCART22 Earns Orphan Drug Designation for Acute Lymphoblastic Leukemia in Europe

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

Here is your guide to important regulatory approvals made by the FDA in May 2024.
May 31st 2024

OncLive’s May Roundup of Key FDA Approvals in Oncology

FDA
May 30th 2024

FDA Approves Liso-Cel for R/R Mantle Cell Lymphoma After 2 Lines of Therapy